SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Cresemba

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2015 (adults) and 2023 (pediatric).
Why 3/10
Cresemba is already approved and marketed with no pending regulatory decision or pivotal readout in the next 12 months. It is a small product within Pfizer's massive portfolio, so even a major sales milestone is immaterial to PFE's share price.
Actionable Insight NEUTRAL

Cresemba is a mature, approved product with no upcoming binary catalysts. The key event to watch is the next quarterly sales milestone from Pfizer to Basilea, which would signal continued commercial momentum, but this is immaterial to Pfizer's stock. For Basilea (SIX: BSLN), Cresemba royalty and milestone income is the primary value driver.

Price Chart

Loading chart...

Executive Summary

Cresemba (isavuconazonium sulfate / isavuconazole) is an approved azole antifungal for invasive aspergillosis and mucormycosis, first FDA-approved in March 2015 with pediatric expansion in December 2023. Pfizer holds exclusive commercialization rights in Europe, China, and Asia Pacific under a license from Basilea Pharmaceutica, paying Basilea milestone payments and mid-teen royalties. Global in-market sales reached $817M over the 12 months through June 2026 (up 25% YoY), making it the world's largest branded antifungal. However, for Pfizer (PFE), a $62.6B revenue company, Cresemba is a small, non-core product not among its top 10 revenue drivers, with no upcoming binary catalysts. The drug is most consequential for Basilea (SIX: BSLN), for whom it is the primary revenue generator.

How It Works

Cresemba is an antifungal medication (a triazole) that works by blocking the production of ergosterol, a key component of fungal cell membranes. Without ergosterol, the fungal cell membrane becomes unstable and the fungus dies. It is given as a prodrug (isavuconazonium sulfate) that converts to the active drug isavuconazole in the bloodstream. It is available in both intravenous (IV) and oral capsule forms, allowing patients to switch from hospital treatment to home therapy.

Trial Status

Cresemba is fully approved by the FDA (March 2015 for adults, expanded December 2023 for children aged 1+), EMA (October 2015), and other global regulators. It is commercially marketed in more than 70 countries by Pfizer (Europe, Asia Pacific, China) and Astellas (US). No pivotal clinical trials are ongoing for new indications.

The Two-Sided Case

▲ Bull Case4
Cresemba is the world's largest branded antifungal for invasive fungal infections, with global in-market sales of $817M in the 12 months through June 2026, growing 25% year-over-year.
The drug benefits from a growing immunocompromised patient population (cancer, transplant, HIV) driving demand for antifungal therapies.
Pediatric approval in December 2023 expanded the addressable market to children as young as one year old, opening a new growth avenue.
Cresemba has a favorable safety profile versus older azoles like voriconazole, supporting continued physician adoption and formulary placement.
▼ Bear Case4
Cresemba is a very small product within Pfizer's $62.6B revenue base and does not appear among Pfizer's top 10 products, making it immaterial to PFE's stock performance.
Patent protection is limited: earliest generic entry estimated around December 2030 to June 2031, and the drug has already faced Paragraph IV challenges, creating long-term revenue risk.
Pfizer pays mid-teen royalties to Basilea on Cresemba sales, meaning the profit margin for Pfizer is lower than for wholly owned products.
The antifungal market faces competition from other azoles (voriconazole, posaconazole) and amphotericin B formulations, which could limit Cresemba's market share growth.

Upcoming Catalysts

  • No upcoming PDUFA dates or pivotal readouts for Cresemba. The next catalyst would be periodic sales milestone announcements from Basilea when Pfizer's cumulative sales cross contractual thresholds, but these are not dated events and are immaterial to Pfizer's stock.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 10

Hover a chip for the title
1 drugs.com2 newsroom.astellas.com3 basilea.com4 basilea.com5 pfizer.com6 pfizer.com7 drugpatentwatch.com8 en.wikipedia.org9 biospace.com10 annualreview.pfizer.com